Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
about
Progress and problems in understanding and managing primary Epstein-Barr virus infectionsAdoptive cell transfer: a clinical path to effective cancer immunotherapyAdoptive T-Cell ImmunotherapyLymphoma Immunotherapy: Current StatusPreventing stem cell transplantation-associated viral infections using T-cell therapyEpstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetT lymphocytes targeting native receptorsEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantPosttransplant lymphoproliferative disease after pediatric solid organ transplantationImmune regulation of human herpesviruses and its implications for human transplantationEpstein-Barr virus infection and posttransplant lymphoproliferative disorderAntiviral T-cell therapyAdoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized miceRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesTherapeutic options in post-transplant lymphoproliferative disorders.Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disordersT-cell-based therapies for malignancy and infection in childhood.Immunotherapy: opportunities, risks and future perspectivesMonitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantationSoluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeEx vivo expansion of human CD8+ T cells using autologous CD4+ T cell helpThe interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersEpstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy.Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Human viruses and cancer.Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapyAge-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Cytotoxic T lymphocytes as immune-therapy in haematological practice.Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantationA case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationRapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections
P2860
Q24597706-402E62F8-85B3-4BEB-ACB7-04D88778ACCFQ24644774-3A9097CB-BEB5-4C3E-B25D-55460A2A327EQ26782845-C9661BAD-91AF-4A70-9CC7-24EC3446B475Q26782902-8B3E098B-2872-4A3C-A3C9-E449A5F65A5CQ26801365-E699D7CB-0B04-411D-B927-207D0DFB9BECQ26822550-C2CB7113-F659-4E93-BF19-4C8FD7542713Q26853345-5F75E28F-7270-4FBC-9609-0CD0B5B9C1AFQ26861623-11518F77-D8FF-46AA-8DC8-210AAB972A06Q26866013-79EE71CC-47DC-4A9F-9939-8371289AC0DEQ26992146-0756A1A4-5E64-4092-AD19-07CEC3CC1271Q27024229-E5EECAAA-4C98-4712-B14C-3D1A70BCB130Q27028006-8219F2A0-3C03-437D-948A-E1B88228925EQ27324235-0029DA36-D00C-467B-9B5D-1DC20E62D23DQ28079823-9F71DB39-57FE-4D9E-8FFE-89CC572968FFQ29393780-6AFC1E55-3261-40C4-B730-87E88ECAE098Q30455714-EC1E700D-D0F6-4CF9-8A21-F9643EAA5A27Q33456742-D01611D6-FABB-40A6-BF46-67F08D7A0AC6Q33634455-B6DD7B95-2C3B-4EF6-B314-240D8E6876E3Q33647028-6F2C9118-D737-4E7A-965A-D4E2BB07C288Q33650689-166BCA30-C9CF-4278-824D-E33D2C89DA76Q33750862-BF0E788F-9CD9-40B3-B63A-D0F4E100F964Q33941012-F8EEE91C-73BB-459E-9BE7-DD17BFE71006Q33962254-729E6F37-826C-40DC-97F6-D407A71EA95FQ34058118-0A592509-1997-4D89-8A98-C1375757D2C9Q34141754-E6C6247E-D02C-462B-8ECC-78CBBA7A6140Q34166602-7E1AD2DF-DEB2-42E5-BBF3-64802A5B4163Q34180551-F8BB7187-741C-4327-BD5B-FED496CA8CAFQ34273968-83ED8C6D-8AD6-4227-A379-7BAB054851C2Q34353696-4D72368E-6178-4804-9A96-D1C50070437EQ34423461-BDEACD27-FB58-4F29-8E9E-51C5DAF3BD98Q34450754-83DEAE21-E3B5-4709-A500-B8DF902995CEQ34622755-F9E3E552-3BBA-4EE1-A725-303DE835797CQ34823783-8FFFF2FF-4158-4728-98A0-DB2A438710B3Q35001573-D9F50F34-490A-48A0-B1A6-969B07D7F938Q35083003-6D6B7DB2-2504-4A13-A7C7-610A029305FAQ35157540-AFBA09EC-E8E7-4D23-9263-B9E882C61DFBQ35485612-0567C305-1E42-4739-9353-7B3B70869839Q35639567-597C793A-D5FE-48E6-85A1-CA13AE2785EEQ35849338-8FB39E5A-D221-44BF-9558-E32A8857F194Q36142490-BEF5269C-1D29-4617-A6F7-7BAE4C00F191
P2860
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@ast
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@en
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@nl
type
label
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@ast
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@en
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@nl
prefLabel
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@ast
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@en
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@nl
P2093
P921
P1433
P1476
Allogeneic cytotoxic T-cell th ...... 2 multicenter clinical trial.
@en
P2093
Alastair MacGilchrist
Christopher Bellamy
Craig D Higgins
David Burns
Deirdre Kelly
Dorothy H Crawford
Gillian Urquhart
Gwen M Wilkie
Karen McAulay
Maher K Gandhi
P304
P356
10.1182/BLOOD-2006-12-063008
P407
P577
2007-04-27T00:00:00Z